<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361190</url>
  </required_header>
  <id_info>
    <org_study_id>2014-07-0062</org_study_id>
    <nct_id>NCT02361190</nct_id>
  </id_info>
  <brief_title>Effects of Fast Acting Testosterone Nasal Spray on Anxiety</brief_title>
  <official_title>Effects of Fast Acting Testosterone Nasal Spray on Anxiety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas at Austin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will test the effects of a fast-acting testosterone nasal spray on the&#xD;
      fear reactions of young men to two distinct anxiety challenges (social and nonsocial) using a&#xD;
      double-blind randomized experimental design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: Test the hypothesis that men administered testosterone nasal spray will result in&#xD;
      lower levels of anxiety (anticipatory and situational) and greater levels of approach&#xD;
      behavior in response to two distinct (social and nonsocial) anxiety challenges relative to&#xD;
      men administered placebo spray.&#xD;
&#xD;
      Aim 2: Test the hypothesis that anxiety challenge type (social versus nonsocial) will&#xD;
      moderate the effects of testosterone administration on subjects' responses to challenge.&#xD;
&#xD;
      Aim 3: Test the hypothesis that rejection sensitivity - heightened sensitivity to evaluative&#xD;
      threat - will moderate the effects of drug condition on response to the two anxiety challenge&#xD;
      tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnitude of behavioral approach</measure>
    <time_frame>30 minutes</time_frame>
    <description>Subjects will be asked to approach a fearful object. Approach will be measured as number of steps (out of 18) the subject completes, with each step bringing the subject closer to the target object</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will inhale approximately 40ml aqueous solution via intranasal route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will inhale approximately 40ml aqueous, testosterone-containing solution via intranasal route</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate</description>
    <arm_group_label>Testosterone nasal spray</arm_group_label>
    <other_name>Testosterone propionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of 1ml aqueous saline spray</description>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, 18 years of age or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male breast cancer&#xD;
&#xD;
          -  Obstructive sleep apnea&#xD;
&#xD;
          -  Suspected or diagnosed prostate cancer&#xD;
&#xD;
          -  Male breast cancer&#xD;
&#xD;
          -  Obstructive sleep apnea&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Heart Disease&#xD;
&#xD;
          -  Liver disease (e.g., hepatitis)&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Tuberculosis or history if positive TB test&#xD;
&#xD;
          -  Infection or fever in the past 7 days&#xD;
&#xD;
          -  Surgeries within the last 6 weeks&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Gastrointestinal disease&#xD;
&#xD;
          -  Respiratory disease (e.g., asthma or chronic bronchitis)&#xD;
&#xD;
          -  Other (Please list)&#xD;
&#xD;
          -  Reynaud's Disease&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Diagnosed hypersensitivity to cold&#xD;
&#xD;
          -  Warfarin (Coumadin) for thinning blood&#xD;
&#xD;
          -  Insulin or any oral drugs for diabetes&#xD;
&#xD;
          -  Propranolol (Inderal)&#xD;
&#xD;
          -  Oxyphenbutazone&#xD;
&#xD;
          -  Imipramine&#xD;
&#xD;
          -  Any kind of corticosteroid drug&#xD;
&#xD;
          -  Insulin&#xD;
&#xD;
          -  Steroids&#xD;
&#xD;
          -  Statins (i.e.., cholesterol lowering drugs)&#xD;
&#xD;
          -  Sleeping pills&#xD;
&#xD;
          -  Drugs to treat hormone disorders&#xD;
&#xD;
          -  Antibiotics in the past 7 days&#xD;
&#xD;
          -  Gastrointestinal disease&#xD;
&#xD;
          -  Pain Killers -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Josephs, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Austin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas at Austin Department of Psychology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas at Austin</investigator_affiliation>
    <investigator_full_name>Robert Josephs</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

